Ketamine decreased striatal [11C]raclopride binding with no alterations in static dopamine concentrations in the striatal extracellular fluid in the monkey brain: Multiparametric pet studies combined with microdialysis analysis

Synapse

Volumn 37, Issue 2, 2000, Pages 95-103

  Tsukada, Hideo ^a   Harada, Norihiro ^a   Nishiyama, Shingo ^a   Ohba, Hiroyuki ^a   Sato, Kengo ^a   Fukumoto, Dai ^a   Kakiuchi, Takeharu ^a  

^a CENTRAL RESEARCH LABORATORY   (Japan)

Author keywords

D2 receptor; Dopamine synthesis; Dopamine transporter; Ketamine; Microdialysis; PET

Indexed keywords

DOPAMINE; DOPAMINE 2 RECEPTOR; KETAMINE; RACLOPRIDE;

ANIMAL EXPERIMENT; ARTICLE; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINE UPTAKE; DOPAMINERGIC TRANSMISSION; EXTRACELLULAR FLUID; LIGAND BINDING; MALE; MICRODIALYSIS; MONKEY; NEUROTRANSMISSION; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR BINDING; STEREOTAXIS;

ANIMALS; BRAIN; CARBON RADIOISOTOPES; CARRIER PROTEINS; COCAINE; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGENTS; DOPAMINE ANTAGONISTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; EXTRACELLULAR SPACE; KETAMINE; LEVODOPA; MACACA MULATTA; MAGNETIC RESONANCE IMAGING; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MICRODIALYSIS; NERVE TISSUE PROTEINS; OSMOLAR CONCENTRATION; RACLOPRIDE; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0033937455     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/1098-2396(200008)37:2<95::AID-SYN3>3.0.CO;2-H     Document Type: Article

References (50)

1. Bacopoulos NG, Redmond DE, Roth RH. 1979. Serotonin and dopamine metabolism in brain regions and cerebrospinal fluid of a primate species: effects of ketamine and fluphenazine. J Neurochem 32:1215-1218.
2. 11C-labelled L-tyrosine and L-DOPA Acta Chem Scand 44:183-188.
3. Bunney BS, Aghajanian GK. 1976. Dopaminergic influence in the basal ganglia: evidence for striatonigral feedback regulation. In: Yahr M, editor. The basal ganglia. New York: Raven Press. p 249-267.
4. Carlsson M, Carlsson A. 1990. Interactions between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease. TINS 13:272-276.
5. 11C]raclopride binding with continuous infusion. J Cereb Blood Flow Metab 17:437-447.
6. 3H]haloperidol. Life Sci 17:993-1002.
7. Dewey SL, Brodie JD, Fowler JS, MacGregor RR, Schlyer DJ, King P, Alexoff D, Volkow ND, Shiue C-Y, Wolf AP, Bendriem B. 1990. Positron emission tomography (PET) studies of dopamine/cholinergic interactions in the baboon brain. Synapse 6:321-327.
8. 18F)-N-methylspiperidol binding in the baboon brain using positron emission tomography (PET). Synapse 7:324-427.
9. 11C-raclopride and positron emission tomography. J Neurosci 12:3773-3780.
10. 11C-raclopride is altered by drugs that modify synaptic dopamine levels. Synapse 13:350-356.
11. Dewey SL, Smith GS, Logan J, Simkowitz P, Brodie JD, Volkow ND, Fowler JS, Wolf AP. 1993b. Effects of central cholinergic blockade on striatal dopamine release measured with positron emission tomography (PET) in normal human subjects. Proc Natl Acad Sci USA 90:11816-11820.
12. Dewey SL, Smith GS, Logan J, Alexoff D, Ding Y-S, King P, Pappas N, Brodie JD, Ashby CR. 1995. Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis. J Neurosci 15:821-829.
13. Donzanti BA, Uretsky NJ. 1984. Antagonism of the hypermotility response induced by excitatory amino acids in the rats nucleus accumbens. Naunyn Schmiedbergs Arch Pharmacol 325:1-7.
14. French E. 1994. Phencyclidine and the midbrain dopamine system: electrophysiology and behavior. Neurotoxicol Teratol 16:355-362.
15. Hattori T, Singh VK, McGeer PL, McGeer EG. 1976. Immunohistochemical localization of choline acetyltransferase containing neostriatal neurons and their relationship with dopaminergic synapse. Brain Res 102:164-173.
16. Huang SH, Barrio J, Phelps M. 1986. Neuroreceptor assay with positron emission tomography; equilibrium versus dynamic approach. J Cerebral Blood Flow Metab 6:515-521.
17. 2 receptor in nonhuman primates. Synapse 10:177-184.
18. Jackson DM, Westlind-Danielsson A. 1994. Dopamine receptors: molecular biology, biochemistry and behavioral aspects. Pharmacol Ther 64:291-369.
19. Kashihara K, Hamamura T, Okumura K, Otsuki S. 1990. Effect of MK-801 on endogenous dopamine release in vivo. Brain Res 528: 80-82.
20. 11C-raclopride against anesthetics in rhesus monkey brain. J Neural Transm 100:147-151.
21. Koepp MJ, Gunn RN, Lawrence AD, Cunningham VJ, Dagher A, Jones T, Brooks DJ, Bench CJ, Grasby PM. 1998. Evidence for striatal dopamine release during a video game. Nature 393:266-268.
22. Koshikawa N, Tomiyama K, Omiya K, Kobayashi M. 1988. Ketamine anesthesia has no effect on striatal dopamine metabolism in rats. Brain Res 444:394-396.
23. Krebs MO, Desce JM, Kermel ML, Gaucy C, Godeheu G, Cheramy A, Glowinski J. 1991. Glutamatergic control of dopamine release in the rat striatum: evidence for presynaptic N-methyl-D-aspartate receptors on dopaminergic nerve terminals. J Neurochem 56:81-85.
24. Logan J, Dewey SL, Wolf AP, Fowler J, Brodie JD, Angrist B, Volkow ND, Gatley SJ. 1991. Effects of endogenous dopamine on measures of [F-18]NMSP binding in the basal ganglia: comparison of stimulations and experimental results from PET studies in baboons. Synapse 9:195-207.
25. 3H-GBR 12935. J Neural Transm 87:1-14.
26. Moghaddam B, Gruen R, Roth R, Bunney B, Adams R. 1990. Effects of 1-glutamate on the release of striatal dopamine: in vivo dialysis and electrochemical studies. Brain Res 518:55-60.
27. Nagatsu T, Levitt M, Udenfriend S. 1964. Tyrosine hydroxylase: the initial steps in norepinephrine biosynthesis. J Biol Chem 239:2910-2920.
28. 11C-methylspiperone binding in vivo: positron emission tomography study using conscious rhesus monkey. Brain Res 663:191-198.
29. Opacka-Juffry J, Ahier RG, Cremer JE. 1991. Nomifensine-induced increase in extracellular striatal dopamine is enhanced by isoflurane anesthesia. Synapse 7:169-171.
30. Raffa RB, Ortegón ME, Robisch DM, Martin GE. 1989. In vivo demonstration of the enhancement of MK-801 by L-glutamate. Life Sci 44:1593-1599.
31. Schmidt WJ. 1986. Intrastriatal injection of DL-2-amino-5-phosphonovaleric acid (AP-5) induces sniffing stereotypy that is antagonized by haloperidol and clozapine. Psychopharmacology 90:123-130.
32. 3H]raclopride: implications for positron emission tomography of the human brain. Synapse 3:96-97.
33. 11C-raclopride. Soc Neurosci Abstr 19:128.
34. 11C-raclopride in normal human subjects. Neuropsychopharmacology 18:18-25.
35. Snider R, Lee JC. 1961. A stereotactic atlas of the monkey brain (Macaca mulatta). Chicago: Chicago University Press.
36. Takechi H, Onoe H, Imamura K, Onoe K, Kakiuchi T, Nishiyama S, Yoshikawa E, Mori S, Kosugi T, Okada H, Tsukada H, Watanabe Y. 1994. Brain activation study by use of positron emission tomography in unanesthetized monkey. Neurosci Lett 182:279-282.
37. 11C]-L-3,4-dihydroxyphenylalanine (DOPA) in the primate by positron emission tomography. Acta Neural Scand 85:166-173.
38. Tsukada H, Lindner KJ, Hartvig P, Långström B. 1994a. Effect of 6R-L-erythro-5,6,7,8-tetrahydrobiopterin on the extracellular levels of dopamine and serotonin in the rat striatum: a microdialysis study with tyrosine or tryptophan infusion. Brain Res 635:59-67.
39. 11C]DOPA turnover in the rat striatum with infusion of L-tyrosine. J Neural Transm (Gen Sect) 95:1-15.
40. 2 receptors in the rat brain: an in vivo study using positron emission tomography. J Neurosci 16:7670-7677.
41. 11C]DOPA disposition in the monkey brain. Brain Res 713:92-98.
42. 11C]raclopride? PET studies combined with microdialysis in conscious monkeys. Brain Res 841: 160-169.
43. Tsukada H, Nishiyama S, Kakiuchi T, Ohba H, Sato K, Harada N, Nakanishi S. 1999b. Isoflurane anesthesia enhances the inhibitory effects of cocaine and GBR12909 on dopamine transporter: PET studies in combination with microdialysis in the monkey brain. Brain Res 849:85-96.
44. Verma A, Moghaddam B. 1996. NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alteration performance in rats: modulation by dopamine. J Neurosci 16:373-379.
45. Volkow ND, Fowler JS, Gatley SJ, Logan J, Wang GJ, Ding YS, Dewey S. 1996. PET evaluation of the dopamine system of the human brain. J Nuclear Med 37:1242-1256.
46. Watanabe M, Okada H, Shimizu K, Omura T, Yoshikawa E, Kosugi T, Mori S, Yamashita T. 1997. A high resolution animal PET scanner using compact PS-PMT detectors. IEEE Trans Nuclear Sci 44: 1277-1282.
47. Weihmuller FB, O'Dell SJ, Cole BN, Marshall JF. 1991. MK-801 attenuates the dopamine-releasing but not the behavioral effects of methamphetamine: an in vivo microdialysis study. Brain Res 549: 230-235.
48. Westerink BHC, Lejeune B, Korf HM, Van Praag. 1977. On the significance of regional metabolism in the rat brain for the classification of centrally acting drugs. Eur J Pharmacol 42:179-190.
49. Willetts J, Balster RL, Leander JD. 1990. The behavioral pharmacology of NMDA receptor antagonists. Trends Pharmacol Sci 11:423-428.
50. Yamamura T, Harada K, Okamura A, Kenmothsu O. 1990. Is the site of action of ketamine anesthesia the N-methyl-D-aspartate receptor? Anesthesiology 72:704-710.